Amneal Pharmaceuticals, Inc. $AMRX Shares Bought by SG Americas Securities LLC

SG Americas Securities LLC boosted its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 2,866.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 784,803 shares of the company’s stock after purchasing an additional 758,343 shares during the period. SG Americas Securities LLC owned approximately 0.25% of Amneal Pharmaceuticals worth $9,889,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. grew its position in Amneal Pharmaceuticals by 75.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 3,761,739 shares of the company’s stock worth $47,398,000 after buying an additional 1,611,698 shares during the last quarter. Westshore Wealth LLC acquired a new stake in shares of Amneal Pharmaceuticals during the 3rd quarter valued at $13,833,000. Allspring Global Investments Holdings LLC boosted its stake in shares of Amneal Pharmaceuticals by 1,440.0% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,135,799 shares of the company’s stock worth $11,790,000 after acquiring an additional 1,062,045 shares in the last quarter. Rubric Capital Management LP grew its holdings in shares of Amneal Pharmaceuticals by 9.1% in the 2nd quarter. Rubric Capital Management LP now owns 11,710,332 shares of the company’s stock worth $94,737,000 after acquiring an additional 974,355 shares during the last quarter. Finally, Hillsdale Investment Management Inc. grew its holdings in shares of Amneal Pharmaceuticals by 89,403.6% in the 3rd quarter. Hillsdale Investment Management Inc. now owns 716,029 shares of the company’s stock worth $7,167,000 after acquiring an additional 715,229 shares during the last quarter. 31.82% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

AMRX has been the subject of several analyst reports. Truist Financial upped their target price on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Zacks Research raised Amneal Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Friday, March 6th. Weiss Ratings restated a “hold (c)” rating on shares of Amneal Pharmaceuticals in a report on Wednesday, January 21st. Finally, Barclays initiated coverage on shares of Amneal Pharmaceuticals in a research note on Monday, December 8th. They set an “overweight” rating and a $15.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $14.20.

Amneal Pharmaceuticals Price Performance

Shares of NASDAQ:AMRX opened at $11.85 on Monday. The company’s fifty day moving average is $13.59 and its two-hundred day moving average is $12.19. Amneal Pharmaceuticals, Inc. has a 12-month low of $6.68 and a 12-month high of $15.42. The company has a market cap of $3.73 billion, a P/E ratio of 51.52 and a beta of 1.34.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.